Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm.
Eur J Ophthalmol
; 32(4): 1890-1899, 2022 Jul.
Article
en En
| MEDLINE
| ID: mdl-35139688
ABSTRACT
Center-involving diabetic macular edema (DME) is a leading cause of vision impairment in working-age adults. While its management is particularly challenging in a poorly compliant population, continuous innovation and the advent of new molecules have improved its outcome. The control of glycemia and of systemic aggravating factors remain essential to slow down progression of disease complications including DME. The indications for macular laser photocoagulation has progressively been phased out as a standard of care and replaced by local intraocular anti-VEGFs biologics and glucocorticoids (GCs). Intravitreal GCs in controlled-release drug delivery systems have allowed to reduce injection frequency and treatment burden. The non biodegradable Fluocinolone Acetonide (FAc) implant allows a long-lasting stabilization of both functional and anatomic improvements. However, adequate patient selection and monitoring through regular follow-up are essential for optimal results. Based on their experience and the latest literature, the aim of the present review is to provide international expert panel consensus on the place of the FAc implant in the treatment algorithm of DME, as well as its safety profile and how to manage it.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Edema Macular
/
Diabetes Mellitus
/
Retinopatía Diabética
Tipo de estudio:
Etiology_studies
/
Guideline
/
Prognostic_studies
Idioma:
En
Revista:
Eur J Ophthalmol
Asunto de la revista:
OFTALMOLOGIA
Año:
2022
Tipo del documento:
Article